Hypersensitivity pneumonitis-coded deaths rose after 2004 across a 32-country analysis
Hypersensitivity pneumonitis rarely sits at the center of mortality surveillance, yet the death certificate data tell a different story: coded mortality increased across a multinational cohort spanning two decades. Using World Health Organization mortality records from 32 countries, investigators identified 7,581 deaths in adults aged 20 years and older between 1999 and 2019, all coded under ICD-10 J67. The pooled age-standardized mortality rate was 0.0394 per 100,000, a small absolute number that still carried a consistent upward trajectory over time.
The pattern was not linear from the start. Mortality remained stable from 1999 through 2004, then climbed with an annual percent change of 7.34% thereafter, producing an average annual percent change of 5.43% over the full study period. In epidemiologic terms, this is the sort of shift that raises two questions at once: whether disease occurrence is changing, and whether the act of naming the disease is changing faster than the disease itself. In a condition that depends heavily on exposure history, radiologic interpretation, pathology, and the wording used on death certificates, both explanations are biologically and administratively plausible.
One sentence stands out for clinicians who care for older adults with progressive interstitial lung disease: the mortality curve climbed steeply with age and reached 0.2977 per 100,000 in people aged 80 years and older.
Age, sex, and country differences point to both biology and recognition
Men had higher coded mortality than women, with rates of 0.0496 versus 0.0317 per 100,000. Yet the increase over time was steeper in women, with an average annual percent change of 6.40% compared with 4.45% in men. The age gradient and sex divergence are clinically meaningful because hypersensitivity pneumonitis is not a single disease in the everyday sense; it is a heterogeneous immune-mediated response to inhaled antigens, shaped by exposure burden, diagnostic delay, comorbid lung injury, and the possibility of progression to fibrotic disease. Older patients often arrive at evaluation after years of cough, dyspnea, and recurrent exposure, when irreversible remodeling has already taken hold.
Between-country heterogeneity was substantial. Among the 25 countries with at least 30 deaths, eight showed a significant increase and two showed a significant decrease. This spread matters because a true change in disease burden should not look identical everywhere. Differences in occupational and environmental exposure, industrialization, farming practices, housing, and bird-related or mold-related antigen contact could all influence risk. At the same time, certification practices differ widely across health systems. Some clinicians may write hypersensitivity pneumonitis on a death certificate only when the diagnosis is established with confidence, while others may default to broader terms such as pulmonary fibrosis, interstitial lung disease, or respiratory failure. In mortality coding, a disease can rise because it is recognized more often, because it is diagnosed earlier, or because it is genuinely becoming more common. Those mechanisms are not mutually exclusive.
Population aging explains part, but not most, of the rise
The analysis included Kitagawa decomposition, which separated the contribution of population age structure from age-specific mortality rates. Among adults aged 40 years and older, population aging accounted for 12.2% of the increase in crude mortality. The rest of the rise came from changes in mortality within age groups, not simply from societies growing older. In practical terms, that means demographic aging alone cannot explain the pattern seen across these countries.
For pulmonologists, occupational physicians, and general internists, the finding reinforces a problem that already exists at the bedside: hypersensitivity pneumonitis can be mistaken for other chronic lung disorders until fibrosis is advanced. Once the inflammatory phase gives way to scarring, the disease behaves less like a reversible immune reaction and more like a chronic progressive interstitial process. Mortality then reflects not only the antigen exposure itself but also delayed exposure removal, persistent inflammation, and the structural lung injury that follows.
The study design cannot resolve those mechanisms, and the authors did not attempt to treat mortality coding as a direct measure of incidence. Death certificate data are vulnerable to misclassification, especially for diseases that lack a single definitive biomarker and often overlap with idiopathic pulmonary fibrosis, occupational lung disease, and other interstitial pneumonias. Even so, the broad multinational signal is hard to ignore. A pooled rate that is low in absolute terms can still carry major clinical importance if it rises steadily over 20 years across diverse health systems.
What the mortality curve means for clinical practice and surveillance
The most immediate implication is for diagnostic vigilance. Hypersensitivity pneumonitis remains a disease of exposure history first, imaging second, and pathology when needed, but clinical suspicion is often the limiting step. When older adults present with unexplained dyspnea, crackles, reduced diffusion capacity, or imaging that suggests fibrotic interstitial lung disease, clinicians need to ask about birds, molds, humidifiers, farming, wood dust, water-damaged buildings, and other inhaled antigens with specificity. Without that history, the diagnosis can drift toward generic fibrosis, and the opportunity to remove the trigger is lost.
A second implication concerns surveillance. Mortality systems can detect broad trends long before they settle into a neat mechanistic explanation. Rising coded deaths across 32 countries suggest that hypersensitivity pneumonitis deserves more attention in public health registries, clinical education, and certification training. If coding practices are shifting, that alone is a signal that recognition has changed. If disease occurrence is also increasing, the need for earlier detection is more urgent.
No single mortality series can separate improved recognition from a true epidemiologic rise. The available data support both possibilities, and the heterogeneity across countries makes a uniform explanation unlikely. What the numbers do establish is that hypersensitivity pneumonitis is no longer a quiet diagnostic afterthought in international mortality data; it is an aging-associated, sex-differentiated, geographically uneven contributor to respiratory death certification that has increased over time and now deserves closer clinical attention in older adults with interstitial lung disease.